[1]Thiam HR, Wong SL, Qiu R, et al. NETosis proceeds by cytoskeleton and endomembrane disassembly and PAD4-mediated chromatin decondensation and nuclear envelope rupture[J]. Proc Natl Acad Sci USA, 2020, 117: 7326-7337. [2]Yapar A, Ali Tokgöz M, Yapar D, et al. Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma[J]. Jt Dis Relat Surg, 2021, 32: 489-496. [3]Huang X, Liu Y, Liang W, et al. A new model of preoperative systemic inflammatory markers predicting overall survival of osteosarcoma: a multicenter retrospective study[J]. BMC Cancer, 2022, 22: 1370. doi: 10.1186/s12885-022-10477-8. [4]叶尔哈那提·胡杜斯, 阿尔恒别克·吐汗拜, 艾克拜尔·尤努斯. NLR、LMR和PLR与骨肉瘤预后的关系[J]. 肿瘤防治研究, 2021, 48: 381-386. [5]Huang X, Liu Y, Liang W, et al. The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients[J]. BMC Cancer, 2022, 22: 1370. doi: 10.3389/fonc.2023.1235158. [6]邓欢, 曹博, 崔昊, 等. 中性粒细胞和淋巴细胞之比与腹膜后脂肪肉瘤术后复发的相关性[J]. 中华实验外科杂志, 2021, 38: 2243-2246. [7]Awaji K, Miyagawa T, Omatsu J, et al. Prognostic relevance of pretreatment peripheral neutrophil count and neutrophil-to-lymphocyte ratio in primary cutaneous angiosarcoma[J]. Acta Derm-Venereol, 2021, 101: adv00527. doi: 10.2340/00015555-3898. [8]García-Ortega DY, Melendez-Fernandez AP, Alvarez-Cano A, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker in extremities undifferentiated pleomorphic sarcoma[J]. Surg Oncol, 2022, 42: 101746. doi: 10.1016/j.suronc.2022.101746. [9]Tepper SC, Lee L, Fice MP, et al. Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and survival in undifferentiated pleomorphic sarcoma (NLR, PLR, and overall survival in UPS)[J]. Surg Oncol, 2023, 49: 101949. doi: 10.1016/j.suronc.2023.101949. [10]Griffiths TT. The baseline neutrophil lymphocyte ratio predicts survival in soft-tissue sarcoma: a 17-year cohort study[J]. J Plast Reconstr Aesthet Surg, 2022,75:1372-1379. doi: 10.1016/j.bjps.2021.11.063. [11]Sato Y, Nakano K, Wang X, et al. Pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of pazopanib treatment for soft-tissue sarcoma[J]. Cancers, 2021, 13: 6266. doi: 10.3390/cancers13246266. [12]Sato Y, Nakano K, Kawaguchi K, et al. Changes in neutrophil-to-lymphocyte ratio predict efficacy of trabectedin for soft-tissue sarcoma[J]. Cancer Diagn Progn, 2021, 1: 303-308. doi: 10.21873/cdp.10040. [13]Sato Y, Nakano K, Fukuda N, et al. Pre-treatment neutrophil-to-lymphocyte ratio predicts efficacy of eribulin for soft-tissue sarcoma[J]. Anticancer Res, 2021, 41: 527-532. doi: 10.21873/anticanres.14804. [14]Yamamoto H, Namba K, Yamamoto H, et al. The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas[J]. Surg Today, 2021, 51: 127-135. doi: 10.1007/s00595-020-02093-5. [15]Ponzetta A, Carriero R, Carnevale S, et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors[J]. Cell, 2019, 178: 346-360.e24. doi: 10.1016/j.cell.2019.05.047. [16]Wang J, Gong M, Xiong Z, et al. Immune-related prognostic genes signatures in the tumor microenvironment of sarcoma[J]. Math Biosci Eng, 2021, 18: 2243-2257. doi: 10.3934/mbe.2021113. [17]Bal O, Acikgoz Y, Yildiz B, et al. Simple and easily accessible prognostic markers in ewing sarcoma; neutrophil-lymphocyte ratio, neutrophil-platelet score and systemic-inflammation index[J]. J Cancer Res Ther, 2023, 19: 1241-1247. doi: 10.4103/jcrt.jcrt_1741_21. [18]Stahl D, Gentles AJ, Thiele R, et al. Prognostic profiling of the immune cell microenvironment in Ewing's sarcoma family of tumors[J]. Oncoimmunology, 2019, 8: e1674113. doi: 10.1080/2162402X.2019.1674113. [19]张海灵, 杨玉, 周倩倩, 等. 微囊藻毒素-LR 处理的中性粒细胞 NETs 促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43: 967-973. [20]Yang L, Liu Q, Zhang X, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25[J]. Nature, 2020, 583: 133-138. doi: 10.1038/s41586-020-2394-6. [21]Leshner M, Wang S, Lewis C, et al. PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures[J]. Front Immunol, 2012, 3: 307. doi: 10.3389/fimmu.2012.00307. [22]Lin Y, Tang H, Teng H, et al. Development and validation of neutrophil extracellular traps-derived signature to predict the prognosis for osteosarcoma patients[J]. Int Immunopharmacol, 2024, 127: 111364. doi: 10.1016/j.intimp.2023.111364. [23]Zhu D, Lu Y, Hu B, et al. Highly-tumor-targeted PAD4 inhibitors with PBA modification inhibit tumors in vivo by specifically inhibiting the PAD4-H3cit-NETs pathway in neutrophils[J]. Eur J Med Chem, 2023, 258: 115619. doi: 10.1016/j.ejmech.2023.115619. [24]Liu B, He S, Li C, et al. Development of a prognostic neutrophil extracellular traps related lncRNA signature for soft tissue sarcoma using machine learning[J]. Front Immunol, 2024, 14: 1321616. doi: 10.3389/fimmu.2023.1321616. [25]Shukrun R, Baron S, Fidel V, et al. Suggested role for neutrophil extracellular trap formation in Ewing sarcoma immune microenvironment[J]. Cancer Sci, 2023: cas.15992. doi: 10.1111/cas.15992. |